
zzso zzso zzso a potent zzso growth factor zzso zzso zzso inhibitor zzso was evaluated in a phase II study to assess its activity in patients with zzso zzso zzso In all, 38 patients with zzso zzso cancer were treated with zzso at a continuous daily oral dose of 150 zzso zzso evaluation was carried out every 8 weeks and zzso zzso were performed before treatment and on day zzso Of 31 zzso patients, 19 zzso had progressive disease and 12 zzso had stable disease zzso The median time to progression for those patients having zzso was 123 days zzso zzso zzso The most common adverse events were rash in 34 patients and zzso in 23 zzso zzso studies were conducted to investigate the effect of zzso on downstream zzso zzso tissue correlations were based on usable tissue from eight match paired zzso samples zzso and on therapy, and showed a statistically significant decrease in the median intensity of both zzso zzso and zzso zzso zzso zzso zzso a week after zzso of zzso No other statistically significant change in zzso markers was zzso zzso was well tolerated with the most common zzso being rash and zzso More than one-third of zzso patients had zzso for a minimum of 8 zzso zzso studies showed a reduction in zzso zzso and zzso in zzso tissue zzso 

